Zynerba shares crushed (again) as back-to-back flops leave lead drug under a cloud
A week ago, Zynerba shares $ZYNE were beaten up after the biotech said its mid-stage study for a cannabis-derived drug had failed to improve …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
